TARGET THERAPY HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES: NEW PROSPECTS FOR TREATMENT


Cite item

Full Text

Abstract

HER2-positive status of patients with breast cancer (BC) is a reliable predictive factor for the brain metastases developed in one third of patients with disseminated HER2 + BC. Lapatinib and Trastuzumab (Bevacizumab, less frequently) are investigated in the treatment of brain metastases of BC. After detection of brain metastases, continuation of therapy with trastuzumab significantly improves overall survival primarily due to effective control of extracranial metastases. It is proved that Trastuzumab and Lapatinib cross the blood-brain barrier in some settings. Combinations of Lapatinib + Capecitabine, Capecitabine + Trastuzumab and Trastuzumab + Lapatinib are promising in the treatment of HER2-positive breast cancer with brain metastases.

References

  1. Cемиглазов В.Ф., Семиглазов В.В. Значение Герцептина в таргетной адъювантной терапии рака молочной железы // Фарматека. 2007. № 18(152). С. 8-11.
  2. Имянитов Е.Н. Герцептин: механизм действия // Современная онкология. 2009. № 11. С. 9-14.
  3. Goldhirsch A, Coates S, Gelber R, et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006;17:1722-776.
  4. Wolff A, Hammond W, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
  5. Pestalossi B, Zahrieh D, Price K, et al. Identifying breast cancer patient at risk for Central Nervous System (CNS) metastases in trials on the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-44.
  6. Brufsky A, Mayer M, Rugo H, et al. RegistHER: patient characteristics and time course of central nervous system metastases in patient with HER2-positive metastatic breast cancer. In Abstract presented at the 2008 ASCO Breast Cancer Symposium, Washington, DC, 5-7 September 2008. (abstr 89).
  7. Yan M. Li, Yong P, Yongkun W, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004;6:459-69.
  8. Cheng X, Hung M. Breast cancer brain metastases. Cancer Metastasis Rev 2007;26:635-43.
  9. Cabioglu N, Sahin A, Morandi P. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 2009;20(6):1013-19
  10. Klos К, Wyszomierski S, Sun М, et a. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research 2006;66:2028-37.
  11. Ono M, Ando M, Yunokawa M, et al. Brain metastases in patient who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 2009;14:48-52.
  12. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43.
  13. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-77.
  14. Yardley DA, Kaufman PA, Mayer M, et al. RegistHER: Patient characteristics and time courseof CNS metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2007;106:263.
  15. Pinder MC, Chang H, Broglio KR, et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases. J Clin Oncol 2007;25:36.
  16. Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-16.
  17. Lower EE, Drosick DR, Blau R, et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003;4:114-19.
  18. Yau T, Swanton C, Chua S, et al: Incidence, pattern, and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006;45:196-201.
  19. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20:56-62.
  20. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era [letter]. J Clin Oncol 2005;23:2114-16.
  21. Pinder M, Chang HY, Broglio KM, et al. Trastuzumab treatment and brain metastases in HER2-positive metastatic breast cancer. In Poster 1018 Presented at the 43rd ASCO Annual Meeting, Chicago, IL, 1-5 June 2007 (Abstr 1018).
  22. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-17.
  23. Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008;31:250-54.
  24. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242-48.
  25. Nam B-H, Kim SY, Han H-S, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
  26. Stemmler H-J, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-28.
  27. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis [letter]. Clin Breast Cancer 2001;2:235.
  28. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7:778-80.
  29. Shojima K, Suzuki E, Saito K, et al. Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 2008;26:75s (Abstr 1138).
  30. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006;15:1373-77.
  31. Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008;19:832-36.
  32. Colossa M, Minenza E, Gori S, et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009;63:1157-59.
  33. Dijkers ECF, Lub-de Hooge M, Kosterink J, et al. Characterization of Zirconium-89 trastuzumab for clinical HER2 immunoPET imaging Slide Presentation at the 43rd ASCO Annual Meeting, Chicago, IL, 1-5 June 2007 (Abstr 3508).
  34. Насхлеташвили Д.Р. Горбунова В.А., Бычков М.Б. и соавт. Современные возможности химиотерапии больных раком молочной железы с метастазами в головной мозг. Материалы VI ежегодной конференции Белые ночи Санкт-Петербурга "Проблемы диагностики и лечения рака молочной железы" 2009. С. 44-47.
  35. Cagatay A, Omer D, Kadri A. Systemic treatment in breast-cancer patients with brain metastasis 2010;11(7):1089-1100.
  36. Lin NU, Carey LA, Liu MC, et al. Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Grouwth Factor 2-Positive Breast Cancer: J Clin Oncol ASCO Annual Meeting Proceedings 2008;26:Abstract 1078.
  37. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27(31):5255-61.
  38. Labidi SI, Bachelot T, Ray-Coquard I, et al. Bevacizumab and paclitaxel for breast-cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009;9(2):118-21.
  39. Collins D, Hill ADK, Young L. Lapatinib: A competitor or companion to trastuzumab? Cancer Treatment Reviews 2009;35:574-581.
  40. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26:1015.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies